These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Longitudinal change in physical activity and its correlates in relapsing-remitting multiple sclerosis. Motl RW; McAuley E; Sandroff BM Phys Ther; 2013 Aug; 93(8):1037-48. PubMed ID: 23599354 [TBL] [Abstract][Full Text] [Related]
3. Patterns and predictors of naturally occurring change in depressive symptoms over a 30-month period in multiple sclerosis. Ensari I; Motl RW; McAuley E; Mullen SP; Feinstein A Mult Scler; 2014 Apr; 20(5):602-9. PubMed ID: 24067897 [TBL] [Abstract][Full Text] [Related]
4. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802 [TBL] [Abstract][Full Text] [Related]
5. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a. Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736 [TBL] [Abstract][Full Text] [Related]
6. Physical activity, social support, and depression: possible independent and indirect associations in persons with multiple sclerosis. Suh Y; Weikert M; Dlugonski D; Sandroff B; Motl RW Psychol Health Med; 2012; 17(2):196-206. PubMed ID: 21781021 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of physical activity and symptoms as predictors of change in functional limitations and disability in multiple sclerosis. Motl RW; McAuley E Rehabil Psychol; 2009 May; 54(2):204-10. PubMed ID: 19469611 [TBL] [Abstract][Full Text] [Related]
8. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671 [TBL] [Abstract][Full Text] [Related]
9. Effects of change in fatigue and depression on physical activity over time in relapsing-remitting multiple sclerosis. Motl RW; McAuley E; Wynn D; Suh Y; Weikert M Psychol Health Med; 2011 Jan; 16(1):1-11. PubMed ID: 21218359 [TBL] [Abstract][Full Text] [Related]
10. Social cognitive variables as correlates of physical activity in persons with multiple sclerosis: findings from a longitudinal, observational study. Suh Y; Weikert M; Dlugonski D; Balantrapu S; Motl RW Behav Med; 2011 Jul; 37(3):87-94. PubMed ID: 21895426 [TBL] [Abstract][Full Text] [Related]
11. Symptoms and physical activity among adults with relapsing-remitting multiple sclerosis. Motl RW; McAuley E; Wynn D; Suh Y; Weikert M; Dlugonski D J Nerv Ment Dis; 2010 Mar; 198(3):213-9. PubMed ID: 20215999 [TBL] [Abstract][Full Text] [Related]
12. Accelerometry in persons with multiple sclerosis: measurement of physical activity or walking mobility? Weikert M; Motl RW; Suh Y; McAuley E; Wynn D J Neurol Sci; 2010 Mar; 290(1-2):6-11. PubMed ID: 20060544 [TBL] [Abstract][Full Text] [Related]
13. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L; Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541 [TBL] [Abstract][Full Text] [Related]
14. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. O'Rourke K; Walsh C; Antonelli G; Hutchinson M Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902 [TBL] [Abstract][Full Text] [Related]
15. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591 [TBL] [Abstract][Full Text] [Related]
16. Lifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel study. Motl RW; McAuley E; Wynn D; Vollmer T Am J Phys Med Rehabil; 2011 May; 90(5):372-9. PubMed ID: 21389842 [TBL] [Abstract][Full Text] [Related]
17. Accurate prediction of cardiorespiratory fitness using cycle ergometry in minimally disabled persons with relapsing-remitting multiple sclerosis. Motl RW; Fernhall B Arch Phys Med Rehabil; 2012 Mar; 93(3):490-5. PubMed ID: 22225573 [TBL] [Abstract][Full Text] [Related]
18. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis. Jung P; Beyerle A; Ziemann U Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509 [TBL] [Abstract][Full Text] [Related]
19. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G; Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262 [TBL] [Abstract][Full Text] [Related]
20. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]